1.A T-cell/histiocyte-rich large B-cell lymphoma involving only the bone marrow.
Blood Research 2015;50(4):192-192
No abstract available.
B-Lymphocytes*
;
Bone Marrow*
;
Lymphoma, B-Cell*
2.Rare bleeding disorders: spectrum of disease and clinical manifestations in the Pakistani population
Rafia MAHMOOD ; Asad MAHMOOD ; Maria KHAN ; Sadia ALI ; Saleem Ahmed KHAN ; Syed Raza JAFFAR
Blood Research 2020;55(3):146-150
Background:
Rare inherited coagulation factor deficiencies constitute an important group of bleeding disorders. A higher frequency of these disorders is seen in areas of high consanguinity.Our aim was to study the prevalence and spectrum of rare inherited bleeding disorders, characterize the severity of the deficiencies, identify different clinical manifestations, and evaluate different treatments provided.
Methods:
This cross-sectional study was conducted in the Department of Haematology, Armed Forces Institute of Pathology Rawalpindi, between January 2014 and December 2018.A detailed history was taken, and an examination was performed. The signs and symptoms were noted, and the patients were diagnosed on the basis of a coagulation profile. The disease severity was assessed using factor assays.
Results:
Among 2,516 patients with suspected coagulation disorders, 774 (30.8%) had an inherited bleeding disorder. Of the 774 patients, 165 (21.3%) had a rare bleeding disorder;91 (55.2%) of them were males, and 74 (44.9%) were females, with a male-to-female ratio of 1.2:1. The median patient age was 9 years 3 months. The most common disorder was factor VII deficiency (46 patients, 27.9%). The most common clinical presentation was bruising in 102 (61.8%) and gum bleeding in 91 (55.2%) patients.
Conclusion
The most common rare bleeding disorder in our population is factor VII deficiency. The prevalence of these bleeding disorders is high in our population due to a high number of consanguineous marriages.
3.New Oral Anticoagulants versus Warfarin for Cerebral Venous Thrombosis: A Multi-Center, Observational Study
Mohammad WASAY ; Maria KHAN ; Haris Majid RAJPUT ; Salman FAROOQ ; Mohammed Ibrahim MEMON ; Suhail Abdulla ALRUKN ; Abdul MALIK ; Foad ABD-ALLAH ; Raja Farhat SHOAIB ; Rizwana SHAHID ; Sadia NISHAT ; Safia AWAN
Journal of Stroke 2019;21(2):220-223
No abstract available.
Anticoagulants
;
Observational Study
;
Venous Thrombosis
;
Warfarin
4.The Safety and Efficacy of Anakinra, an Interleukin-1 Antagonist in Severe Cases of COVID-19: A Systematic Review and Meta-Analysis
Manoj Kumar Reddy SOMAGUTTA ; Maria Kezia Lourdes PORMENTO ; Pousette HAMID ; Alaa HAMDAN ; Muhammad Adnan KHAN ; Rockeven DESIR ; Rupalakshmi VIJAYAN ; Saloni SHIRKE ; Rishan JEYAKUMAR ; Zeryab DOGAR ; Sarabjot Singh MAKKAR ; Prathima GUNTIPALLI ; Ngaba Neguemadji NGARDIG ; Manasa Sindhura NAGINENI ; Trissa PAUL ; Enkhmaa LUVSANNYAM ; Chala RIDDICK ; Marcos A. SANCHEZ-GONZALEZ
Infection and Chemotherapy 2021;53(2):221-237
This study aims to assess anakinra's safety and efficacy for treating severe coronavirus disease 2019 (COVID-19). Numerous electronic databases were searched and finally 15 studies with a total of 3,530 patients, 757 in the anakinra arm, 1,685 in the control arm were included. The pooled adjusted odds ratio (OR) for mortality in the treatment arm was 0.34 (95% confidence interval [CI], 0.21 - 0.54, I2 = 48%), indicating a significant association between anakinra and mortality. A significant association was found regarding mechanical ventilation requirements in anakinra group compared to the control group OR, 0.68 (95% CI, 0.49 - 0.95, I2 = 50%). For the safety of anakinra, we evaluated thromboembolism risk and liver transaminases elevation. Thromboembolism risk was OR, 1.59 (95% CI, 0.65 - 3.91, I2 = 0%) and elevation in liver transaminases with OR was 1.35 (95% CI, 0.61 - 3.03, I2 = 76%). Both were not statistically significant over the control group. Anakinra is beneficial in lowering mortality in COVID-19 patients. However, these non-significant differences in the safety profile between the anakinra and control groups may have been the result of baseline characteristics of the intervention group, and further studies are essential in evaluating anakinra's safety profile.
5.The Safety and Efficacy of Anakinra, an Interleukin-1 Antagonist in Severe Cases of COVID-19: A Systematic Review and Meta-Analysis
Manoj Kumar Reddy SOMAGUTTA ; Maria Kezia Lourdes PORMENTO ; Pousette HAMID ; Alaa HAMDAN ; Muhammad Adnan KHAN ; Rockeven DESIR ; Rupalakshmi VIJAYAN ; Saloni SHIRKE ; Rishan JEYAKUMAR ; Zeryab DOGAR ; Sarabjot Singh MAKKAR ; Prathima GUNTIPALLI ; Ngaba Neguemadji NGARDIG ; Manasa Sindhura NAGINENI ; Trissa PAUL ; Enkhmaa LUVSANNYAM ; Chala RIDDICK ; Marcos A. SANCHEZ-GONZALEZ
Infection and Chemotherapy 2021;53(2):221-237
This study aims to assess anakinra's safety and efficacy for treating severe coronavirus disease 2019 (COVID-19). Numerous electronic databases were searched and finally 15 studies with a total of 3,530 patients, 757 in the anakinra arm, 1,685 in the control arm were included. The pooled adjusted odds ratio (OR) for mortality in the treatment arm was 0.34 (95% confidence interval [CI], 0.21 - 0.54, I2 = 48%), indicating a significant association between anakinra and mortality. A significant association was found regarding mechanical ventilation requirements in anakinra group compared to the control group OR, 0.68 (95% CI, 0.49 - 0.95, I2 = 50%). For the safety of anakinra, we evaluated thromboembolism risk and liver transaminases elevation. Thromboembolism risk was OR, 1.59 (95% CI, 0.65 - 3.91, I2 = 0%) and elevation in liver transaminases with OR was 1.35 (95% CI, 0.61 - 3.03, I2 = 76%). Both were not statistically significant over the control group. Anakinra is beneficial in lowering mortality in COVID-19 patients. However, these non-significant differences in the safety profile between the anakinra and control groups may have been the result of baseline characteristics of the intervention group, and further studies are essential in evaluating anakinra's safety profile.